Join Digital Education Committee Member and podcast host Melissa E. Middeldorp, MPH, PhD, and her guests Eue-Keun Choi, MD, PhD, and Sandeep Prabhu, MBBS, PhD for this week’s Lead episode. This episode was recorded LIVE at APHRS 2025 in Yokohama, Japan.
The DECAF trial investigated whether continuing regular caffeinated coffee consumption versus complete abstinence affected the recurrence of atrial fibrillation (AF) or atrial flutter in patients after successful cardioversion. Over six months in this randomized study of 200 adults, those who drank at least one cup of caffeinated coffee daily had a significantly lower rate of AF or flutter recurrence compared to those who abstained (47% vs. 64%), suggesting moderate coffee intake may be safe and potentially beneficial for rhythm stability in this setting.
Learning Objectives
-
Evaluate the impact of caffeinated coffee consumption versus abstinence on atrial fibrillation recurrence following cardioversion.
-
Interpret the design and key outcomes of the DECAF randomized clinical trial and their relevance to clinical practice.
-
Apply the trial findings to patient counseling regarding caffeine intake and atrial fibrillation management.
Article Authors
Christopher X. Wong, MBBS, MPH, PhD; Christopher C. Cheung, MD, MPH; Gabrielle Montenegro, BA, Hannah H. Oo, BS; Isabella J. Peña, BA; Janet J. Tang, MPH, PhD; Samuel J. Tu, MBBS; Grace Wall, BA1; Thomas A. Dewland, MD; Joshua D. Moss, MD; Edward P. Gerstenfeld, MD; Zian H. Tseng, MD, MAS; Henry H. Hsia, MD; Randall J. Lee, MD, PhD; Jeffrey E. Olgin, MD; Vasanth Vedantham, MD; Melvin M. Scheinman, MD; Catherine Lee, PhD; Prashanthan Sanders, MBBS, PhD; Gregory M. Marcus, MD, MAS
Podcast Contributors
Melissa E. Middeldorp, MPH, PhD
Eue-Keun Choi, MD, PhD
Sandeep Prabhu, MBBS, PhD
Article and Speaker information: Download
Listen on Heart Rhythm 365
Listen on iHeart
Listen on Spotify
Listen on Apple Podcasts
Topic
- The Lead
Resource Type
- Podcasts
Related Resources
The Lead
Podcasts
The Lead Episode 155: A Discussion of A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation versus Anti-Arrhythmic Drug Therapy as a First Line Treatment for Persistent Atrial Fibrillation (AVANT GUARD)
June 11, 2026
The Lead
Podcasts
The Lead Episode 154: A Discussion of Safety and Effectiveness of a Dual-Energy Focal Ablation Catheter to Treat Paroxysmal Atrial Fibrillation: 6- Month Results of the FlexPulse IDE Study
June 4, 2026
EP Edge Journal Watch
Podcasts
Inaugural EP Edge Journal Watch with HRS: AVANT GUARD, LAA Closure, OCEAN, and the ALONE-AF Cognitive Substudy
May 29, 2026